Key result
Riociguat significantly improves exercise capacity and secondary efficacy endpoints in pulmonary arterial hypertension.
Why the study?
Does riociguat improve exercise capacity in patients with pulmonary arterial hypertension?
Does riociguat improve exercise capacity in patients with pulmonary arterial hypertension?
Riociguat provides significant improvement in exercise capacity for patients with pulmonary arterial hypertension.
Answers are grounded in this paper and cite their sources.
Riociguat improves exercise capacity in pulmonary arterial hypertension; opens a new treatment axis for soluble guanylate cyclase stimulation.
Riociguat significantly improved exercise capacity and secondary efficacy end points in patients with pulmonary arterial hypertension. (Funded by Bayer HealthCare; PATENT-1 and PATENT-2 ClinicalTrials.gov numbers, NCT00810693 and NCT00863681, respectively.).
No takes yet. Share an insight, caveat, or question.
Ghofrani et al. (2013) studied this question. Riociguat significantly improved exercise capacity and secondary efficacy endpoints in patients with pulmonary arterial hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: